Policy Efforts 

Antimicrobial Resistance Committee

To advance through public policy and advocacy activities the development of new antimicrobial agents where unmet need exists and the reduction of the occurrence of antimicrobial resistance, in general, stressing in particular the recommendations contained in IDSA’s Combating Antimicrobial Resistance: Policy Recommendations to Save Lives, Policy Statement on Antimicrobial Stewardship, positions taken as part of the Bad Bugs, No Drugs/10 x ’20 Initiative, and other IDSA policy statements.

Diagnostics Task Force

To evaluate current trends related to the research, development, approval, manufacture, regulation and uptake of infectious diseases diagnostics at a time of rapid evolvement in the field; to assess and prioritize unmet diagnostics needs (including for clinical, public health, and global health purposes), particularly in the area of point-of-care diagnostics, and determine the degree of misalignment with current trends; to understand the challenges to diagnostics innovation and uptake from the perspective of key stakeholders (industry, governments, health care providers and payors/funders) and consider potential policy options for overcoming these challenges; and to make recommendations to the Board of Directors on policy solutions that will improve the U.S. government’s capacity to address unmet diagnostics needs in this country as well as in resource-constrained countries.

Public Health Committee

To serve as the lead entity making recommendations to the Board of Directors on public health and emergency preparedness policy, including issues and policy related to increasing immunization coverage (with a particular focus on adult immunizations).

Research  Committee

The goal of the Research Committee is to establish IDSA as an important voice on issues related to research on infectious diseases (reports to the Board of Directors). The committee makes recommendations to promote research and new advancements in infectious diseases;monitor developments and make recommendations related to federal support for biomedical research; and make recommendations on activities/issues under its purview that involve federal legislation and regulation.